Balance-sheet StrengthAn equity-heavy capital structure and very low leverage materially reduce refinancing and solvency risk, providing durable financial flexibility. This supports multi-year investments, M&A optionality, and the ability to absorb revenue volatility without stressing liquidity or forcing short-term cost cuts.

Robotics Licensing MomentumRising license revenues and an expanding robotics pipeline create a higher-margin, repeatable revenue stream. Structural adoption of surgical robotics and multi-customer development relationships increase stickiness, support recurring licensing and services, and deepen long-term OEM partnerships.

Sustainably High Gross MarginsConsistently strong gross margins reflect scalable software and simulation-driven revenue with limited per-unit cost escalation. High product margins underpin operating profitability even through lumpiness, enabling reinvestment in R&D and margin recovery when revenue normalizes.

Bears Say

Intuitive MoU CancellationLoss of a large anticipated robotics partner creates a meaningful, multi-figure revenue hole and reduces visibility for 2026. This structural customer setback slows planned license growth, increases dependency on other OEMs, and raises execution risk for hitting multi-year sales targets.

Volatile Cash ConversionIrregular operating cash flow and working-capital swings undermine predictability of internally generated funding. For a growth-oriented med-tech business, inconsistent cash conversion complicates budgeting, limits steady reinvestment or buyback flexibility, and raises sensitivity to timing of large deals.

Integration And IU LossesAcquisition-related integration setbacks and near-term operating losses can dilute consolidated margins and distract management. If ultrasound synergies and U.K. sales do not scale, the business faces persistent profit drag and execution risk that could slow margin recovery.

Surgical Science Sweden AB News

Surgical Science Sweden Balances Record Quarter With 2026 Risk

Surgical Science Sweden AB (($SE:SUS)) has held its Q4 earnings call. Read on for the main highlights of...

17d ago

Surgical Science price target lowered to SEK 40 from SEK 120 at Berenberg

Berenberg analyst Simon Jonsson lowered the firm’s price target on Surgical Science (SUSRF) to SEK 40 from SEK...

3M ago

SUS FAQ

What was Surgical Science Sweden AB’s price range in the past 12 months?

Surgical Science Sweden AB lowest stock price was kr23.70 and its highest was kr162.80 in the past 12 months.

What is Surgical Science Sweden AB’s market cap?

Surgical Science Sweden AB’s market cap is kr1.60B.

When is Surgical Science Sweden AB’s upcoming earnings report date?

Surgical Science Sweden AB’s upcoming earnings report date is May 20, 2026 which is in 71 days.

How were Surgical Science Sweden AB’s earnings last quarter?

Surgical Science Sweden AB released its earnings results on Feb 19, 2026. The company reported kr0.65 earnings per share for the quarter, missing the consensus estimate of kr0.673 by -kr0.023.

Is Surgical Science Sweden AB overvalued?

According to Wall Street analysts Surgical Science Sweden AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Surgical Science Sweden AB pay dividends?

Surgical Science Sweden AB does not currently pay dividends.

What is Surgical Science Sweden AB’s EPS estimate?

Surgical Science Sweden AB’s EPS estimate is 0.37.

How many shares outstanding does Surgical Science Sweden AB have?

Surgical Science Sweden AB has 51,026,237 shares outstanding.

What happened to Surgical Science Sweden AB’s price movement after its last earnings report?

Surgical Science Sweden AB reported an EPS of kr0.65 in its last earnings report, missing expectations of kr0.673. Following the earnings report the stock price went up 16.961%.

Which hedge fund is a major shareholder of Surgical Science Sweden AB?

Currently, no hedge funds are holding shares in SE:SUS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Surgical Science Sweden AB

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence-based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim ST develops to train surgical technologists and surgical assistants; and LapSim essence, a portable and ready-to-use VR simulator. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach; simbionix simulators; and robotic surgery simulators. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.